Shopping Cart
Remove All
Your shopping cart is currently empty
BAY 73-6691 racemate (Rac-BAY 73-6691) is a phosphodiesterase 9A (PDE9A) inhibitor used for research in Parkinson's disease.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | $258 | 7-10 days | 7-10 days | |
| 1 mL x 10 mM (in DMSO) | $278 | 7-10 days | 7-10 days |
| Description | BAY 73-6691 racemate (Rac-BAY 73-6691) is a phosphodiesterase 9A (PDE9A) inhibitor used for research in Parkinson's disease. |
| In vitro | The BAY 73-6691 racemate is the BAY 73-6691 racemate. Treatment with BAY 73-6691 (50, 100, 150, and 200μg/mL) attenuated the cytotoxicity and oxidative stress of Aβ25-35-induced SH-SY5Y cells. [3] |
| In vivo | BAY 73-6691 (1 mg/kg/ day and 5 mg/kg/ day) for 95 days. The 5/6Nx rats developed albuminuria, decreased serum creatinine clearance (Ccr), and increased serum troponin T levels. [2] In A mouse model, BAY 73-6691 (intraperitoneal injection) protected hippocampal neurons from oxidative damage induced by Aβ25-35. [3] |
| Synonyms | Rac-BAY 73-6691, BAY 736691 racemate |
| Molecular Weight | 356.73 |
| Formula | C15H12ClF3N4O |
| Cas No. | 794568-90-4 |
| Smiles | O=C1N=C(NC2=C1C=NN2C=3C=CC=CC3Cl)CC(C)C(F)(F)F |
| Relative Density. | 1.52 g/cm3 (Predicted) |
| Color | White |
| Appearance | Solid |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (224.26 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 5 mg/mL (14.02 mM), Sonication is recommeded. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.